THTX > 2.81 up 26% > Theratechnologies Sees Positive Data for Treatment of Nonalcoholic Steatohepatitis
6:21 am ET July 24, 2020 (Dow Jones) Print
By Chris Wack
Theratechnologies Inc. on Thursday reported new data that the company said further supports the potential role of tesamorelin in the treatment of HIV-associated nonalcoholic steatohepatitis.
The biopharmaceutical company said the new data are derived from a sub-analysis of the Phase 2 study evaluating the effect of tesamorelin on the transcriptome of the liver biopsies in people living with HIV-associated nonalcoholic fatty liver disease.
Theratechnologies said the data show that tesamorelin improves oxidative phosphorylation gene expression, and decreases gene expression involved in inflammation, tissue repair and cell division. The company said the data also support the clinical relevance for the development of tesamorelin as a potential treatment for liver diseases.
Theratechnologies shares were up 40% to $3.13 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
New York Yankees and Duke Basketball
